Level of DNA topoisomerase IIα mRNA predicts the treatment response of relapsed acute leukemic patients

Leukemia Research

Volumn 33, Issue 7, 2009, Pages 902-907

  Wang, Yan Hua ^a   Takanashi, Minoko ^b   Tsuji, Kazue ^a   Tanaka, Norina ^a   Shiseki, Masayuki ^a   Mori, Naoki ^a   Motoji, Toshiko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Japanese Red Cross Tokyo Blood Center   (Japan)

Author keywords

Acute leukemia; DNA topoisomerase II (Topo II ); Drug sensitivity; Multidrug resistance (MDR); Real time RT PCR

Indexed keywords

ACLARUBICIN; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IIALPHA; DOXORUBICIN; ENOCITABINE; ETOPOSIDE; IDARUBICIN; IMATINIB; MERCAPTOPURINE; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; RETINOIC ACID; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MYELODYSPLASTIC SYNDROME; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; BLAST CRISIS; CELL CYCLE; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67349162929     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.12.012     Document Type: Article

References (46)

1. McKenna S.L. Multidrug resistance in leukemia. Br J Haematol 96 (1997) 659-674
2. Valkov N.I., and Sullivan D.M. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin Hematol 34 (1997) 48-62
3. Wang J.C. Cellular role of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3 (2002) 430-440
4. Berger J.M., Gamblin S.J., Harrison S.C., and Wang J.C. Structure and mechanism of DNA topoisomerase II. Nature 379 (1996) 225-232
5. Kellner U., Sehested M., Jensen P.B., Gieseler F., and Rudolph P. Culprit and victim-DNA topoisomerase II. Lancet Oncol 3 (2002) 235-243
6. McKenna S.L., West R.R., Whittaker J.A., Padua R.A., and Holmes J.A. Topoisomerase II α expression in acute myeloid leukaemia and its relationship to clinical outcome. Leukemia 8 (1994) 1498-1502
7. Beck J., Handgretinger R., Dopfer R., Klingebiel T.G., Niethammer D., and Gekeler V. Expression of mdr1, mrp, topoisomerase IIα/β, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol 89 (1995) 356-363
8. Towatari M., Adachi K., Marunouchi T., and Saito H. Evidence for a critical role of DNA topoisomerase IIα in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line. Br J Haematol 101 (1998) 548-551
9. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58 (1989) 351-375
10. Heck M.M.S., Hittelman W.N., and Earnshaw W.C. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85 (1988) 1086-1090
11. Woessner R.D., Mattern M.R., Mirabelli C.K., Johnson R.K., and Drake F.H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2 (1991) 209-214
12. Isaacs R.J., Davies S.L., Sandri M.I., Redwood C., Wells N.J., and Hickson I.D. Physiological regulation of eukaryotic topoisomerase II. Bio et Biophysica Acta 1400 (1998) 121-137
13. Kaufmann S.H., Karp J.E., Miller C.B., Schneider F., Zwelling L.A., Cowan K., et al. Topoisomerase II level and drug sensitivity in adult acute myelogenous leukemia. Blood 83 (1994) 517-530
14. Klumper E., Pieters R., Veerman A.J.P., Huismans D.R., Loonen A.H., Hählen K., et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 86 (1995) 3861-3868
15. Galmarini C.M., Thomas X., Calvo F., Rousselot P., El Jafaari A., Cros E., et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 26 (2002) 621-629
16. Satake S., Sugawara I., Watanabe M., and Takami H. Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines. Cancer Lett 116 (1997) 33-39
17. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103 (1985) 620-625
18. Okamoto T., Kanamaru A., Shimazaki C., Motoji T., Takemoto Y., Takahashi M., et al. Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan adult leukemia study group (JALSG): results of an interim analysis. Int J Hematol 72 (2000) 200-205
19. Miyawaki S., Tanimoto M., Kobayashi T., Minami S., Tamura J., Omoto E., et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabin, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol 70 (1999) 97-104
20. Ohtake S., Miyawaki S., Fujita H., Kiyoi H., Shinagawa K., Usui N., et al. Randomized clinical trial of induction therapy comparing intensified daunorubicin with idarubicin in patients with previously untreated de novo acute myeloid leukemia (JALSG AML201 Study). Blood 108 (2006) [abstract 2000]
21. Asou N., Kishimoto Y., Kiyoi H., Okada M., Kawai Y., Tsuzuki M., et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 110 (2007) 59-66
22. Ohtake S., Miyawaki S., Tanimoto M., Kuriyama K., Matusda S., Hatake K., et al. Randomized clinical trial of response-oriented individualized versus fixed schedule induction chemotherapy in adult acute myeloid leukemia: the JALSG AML95 Study. Blood 10 (1999) 298a [abstract 1330]
23. Slater D.E., Mertelsmann R., Koziner B., Higgins C., McKenzie S., Schauer P., et al. Lymphoblastic lymphoma in adults. J Clin Oncol 4 (1986) 57-67
24. Towatari M., Yanada M., Usui N., Takeuchi J., Sugiura I., Takeuchi M., et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104 (2004) 3507-3512
25. Hoelzer D., Ludwig W.D., Thiel E., Gassmann W., Löffler H., Fonatsch C., et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87 (1996) 495-508
26. Takeuchi J., Kyo T., Naito K., Sao H., Takahashi M., Miyawaki S., et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 16 (2002) 1259-1266
27. Martino R., Bellido M., Brunet S., Altés A., Sureda A., Guárdia R., et al. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial. Haematologica 84 (1999) 505-510
28. Yasunami T., Wang Y.H., Tsuji K., Takanashi M., Yamada Y., and Motoji T. Multidrug resistance protein expression of adult T-cell leukemia/lymphoma. Leuk Res 31 (2007) 465-470
29. Zhou R., Marianne F.S., Kronenwett U., Gruber A., Liliemark J., and Liliemark E. Real-time RT-PCR for the determination of topoisomerase II mRNA level in leukaemic cells. Leuk Res 26 (2002) 487-494
30. Wang Y.H., Motoji T., Motomura S., Shiozaki H., Tsuruo T., and Mizoguchi H. Recovery of drug sensitivity by MS-209, a new multidrug resistance-reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line. Eur J Haematol 58 (1997) 186-194
31. Motomura S., Motoji T., Takanashi M., Wang Y.H., Shiozaki H., Sugawara I., et al. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood 91 (1998) 3163-3171
32. Legrand O., Simonin G., Zittoun R., and Marie J.P. Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia 12 (1998) 1367-1374
33. Block A.L., Bauer K.D., Williams T.J., and Seidenfeld J. Experimental parameters and a biological standard for acridine orange detection of drug-induced alterations in chromatin condensation. Cytometry 8 (1987) 163-169
34. Beck J., Niethammer D., and Gekeler V. MDR1, MRP, topoisomerase IIα/β, and cyclin A gene expression in acute and chronic leukemias. Leukemia Suppl. 3 (1996) S39-S45
35. Beck J., Handgretinger R., Klingebiel T., Dopfer R., Schaich M., Ehninger G., et al. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia 10 (1996) 426-433
36. Gekeler V., Frese G., Noller A., Handgretinger R., Wilisch A., Schmidt H., et al. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase π gene expression in primary and relapsed state adult and childhood leukaemias. Br J Cancer 66 (1992) 507-517
37. Lohri A., van Hille B., Bacchi M., Fopp M., Joncourt F., Reuter J., et al. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK). Eur J Haematol 59 (1997) 206-215
38. Grandgirard N., Ly-Sunnaram B., Ferrant D., Gandemer V., Edan C., Le Gall E., et al. Impact of topoisomerase II alpha and spermine on the clinical outcome of children with acute lymphoblastic leukemia. Leuk Res 28 (2004) 479-486
39. Fry A.M., Chresta C.M., Davies S.M., Walker M.C., Harris A.L., Hartley J.A., et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51 (1991) 6592-6595
40. Kasahara K., Fujiwara Y., Sugimoto Y., Nishio K., Tamura T., Matsuda T., et al. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 84 (1992) 113-118
41. Stevnsner T., and Bohr V.A. Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair. Carcinogenesis 14 (1993) 1841-1850
42. Rudolph P., Kellner U., Chassevent A., Collin F., Bonichon F., Parwaresch R., et al. Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma. A multivariate study. Am J Pathol 150 (1997) 1997-2007
43. Rudolph P., Olsson H., Bonatz G., Ratjen V., Bolte H., Baldetorp B., et al. Correlation between p53, c-erbB-2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 187 (1999) 207-216
44. Klumper E., Giaccone G., Pieters R., Broekema G., van Ark-Otte J., van Wering, et al. Topoisomerase IIα gene expression in childhood acute lymphoblastic leukemia. Leukemia 9 (1995) 1653-1660
45. Uggla B., Möllgård L., Ståhl E., Mossberg L.L., Karlsson M.G., Paul C., et al. Expression of topoisomerase IIα in the G0/G1 cell cycle phase of fresh leukemic cells. Leuk Res 25 (2001) 961-966
46. Motoji T., Motomura S., Wang Y.H., Tsuji K., Takanashi M., Shiozaki H., et al. Clinical significance of P-glycoprotein in acute leukemia and a strategy to overcome drug resistance. In: Jeffries L.P. (Ed). Frontiers in cancer research (2006), Nova Science Publishers, New York p. 123-51